- Home
- BTBD vs RDHL Comparison
BTBD vs RDHL Comparison
Compare BTBD & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- RDHL
- Stock Information
- Founded
- BTBD 1987
- RDHL 2009
- Country
- BTBD United States
- RDHL Israel
- Employees
- BTBD N/A
- RDHL N/A
- Industry
- BTBD Restaurants
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- RDHL Health Care
- Exchange
- BTBD Nasdaq
- RDHL Nasdaq
- Market Cap
- BTBD 10.5M
- RDHL 11.2M
- IPO Year
- BTBD 2021
- RDHL N/A
- Fundamental
- Price
- BTBD $1.61
- RDHL $6.74
- Analyst Decision
- BTBD
- RDHL
- Analyst Count
- BTBD 0
- RDHL 0
- Target Price
- BTBD N/A
- RDHL N/A
- AVG Volume (30 Days)
- BTBD 6.9K
- RDHL 14.9K
- Earning Date
- BTBD 11-13-2024
- RDHL 11-26-2024
- Dividend Yield
- BTBD N/A
- RDHL N/A
- EPS Growth
- BTBD N/A
- RDHL N/A
- EPS
- BTBD N/A
- RDHL N/A
- Revenue
- BTBD $14,647,844.00
- RDHL $3,707,000.00
- Revenue This Year
- BTBD N/A
- RDHL $224.90
- Revenue Next Year
- BTBD N/A
- RDHL $82.69
- P/E Ratio
- BTBD N/A
- RDHL N/A
- Revenue Growth
- BTBD 4.20
- RDHL N/A
- 52 Week Low
- BTBD $1.25
- RDHL $6.35
- 52 Week High
- BTBD $3.05
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- BTBD 49.41
- RDHL 35.94
- Support Level
- BTBD $1.52
- RDHL $6.35
- Resistance Level
- BTBD $1.69
- RDHL $7.37
- Average True Range (ATR)
- BTBD 0.08
- RDHL 0.41
- MACD
- BTBD -0.00
- RDHL -0.10
- Stochastic Oscillator
- BTBD 54.85
- RDHL 18.33
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.